A study by researchers at the University of California, Riverside and UC Irvine reviewed 341 pivotal trials conducted from 2017 to 2023. The authors found that only a small share of the trials reflect the United States racial and ethnic makeup, with Black and Hispanic people increasingly underrepresented after 2021. Asian representation rose during the period, while white participation remained largely stable.
The researchers explain that many pivotal trials follow International Council for Harmonisation (ICH) standards and are run across a few regions such as the US, Europe, China and Japan, which concentrates evidence in those places. Sub-Saharan Africa and much of Latin America host very few pivotal trials and are often left out of the data that shapes medicines for Americans.
The paper, published in Communications Medicine, recommends more diversity earlier in drug development, including setting diversity goals, choosing testing locations to reflect local health needs and collecting biological samples to study drug responses.
Difficult words
- pivotal — very important for the result or decision
- underrepresent — to show fewer people than existunderrepresented
- representation — presence of people from different groups
- harmonisation — making rules or standards the same
- diversity — variety of different people or elements
- collect — to bring together items or informationcollecting
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Why is it important for clinical trials to reflect the United States racial and ethnic makeup?
- What problems might happen if Sub-Saharan Africa and much of Latin America are left out of pivotal trials?
- What steps could researchers take to increase diversity earlier in drug development?
Related articles
Needle-free spray delivers last-resort antibiotics
Researchers developed a needle-free spray-mist device to push last-resort antibiotics through the skin into infected tissue. The method aims to treat drug-resistant infections while reducing organ damage linked to intravenous delivery.
Blocking a key immune signal may prolong post-surgery pain
A study led by Geoffroy Laumet found that blocking the immune molecule TNF-α after surgery in mice made pain last longer. The authors warn this does not mean stopping all anti-inflammatory treatment and call for targeted approaches.
Exercise helps reduce 'chemo brain' during chemotherapy
Researchers tested a home exercise program during chemotherapy and found patients who followed it kept daily activity and reported clearer thinking. The trial compared a six-week exercise plan with standard care during treatment.